Despite continued advances in screening, the PSA test and the Digital Rectal Exam performed by doctors may not do enough to reduce the risk of dying from prostate cancer. This is the finding reported in the January 9th issue of the "Archives of Internal Medicine."
The study author, Dr. John Concato M.D/M.P.H. from the Veterans Affairs Connecticut Healthcare System and Yale University, noted that in study of 1,002 men aged 50 and older that those who received screening had a mortality rate equal to or greater than those men who did not receive screening. The implication of this, according to Dr. Concato is "if prostate cancer screening prevented death, fewer men who died would have received screening compared to the men who were living. In addition, "screening was not found to reduce mortality among men who were younger or healthier."
The Responsible Approach:
The Establishment Medical Community has reacted harshly to Dr. Concato's findings and has questioned the advisability of discounting the value PSA and Digital Rectal Exams. Based on this, the responsible approach continues to be to speak regularly with your doctor about PSA screening and your risk of prostate cancer and Benign Prostate Hyperplasia (BPH). BPH is the medical term used by doctors to define an enlarged prostate. An enlarged prostate may be the result of an inflection, recent exercise or sex and several other factors. BPH is fairly common in older men and while not considered very serious should also be evaluated by a licensed medical professional.
For more information on the early warning signs of BPH and the natural alternatives available to men, you may want to visit the Biocentric Health web site. A nutritional supplement that supports a healthy prostate is Prostaris. You can also learn more about Prostaris by calling 877-880-7800
